Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.65 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619097 | 0.93 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL1619094 | 0.90 | HDAC1 (0.65) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL10231659 | 0.88 | HDAC1 (0.65) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL1617493 | 0.87 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL1618956 | 0.86 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL1619073 | 0.86 | HDAC3 (0.66) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL1618988 | 0.86 | HDAC6 (0.66) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL1619078 | 0.85 | HDAC6 (0.64) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL1618953 | 0.84 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL1618699 | 0.84 | HDAC1 (0.63) | HDAC1HDAC3HDAC2HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | disclosed |
| US-8557825-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-8557825-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF VAN (BE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF VAN (BE) | 2012-04-12 | — | — | US | disclosed |
| US-8097611-B2 | Sulfonyl-derivatives as novel or histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| US-8097611-B2 | Sulfonyl-derivatives as novel or histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| US-7709487-B2 | anticancer agents; can be combined with other HDAC inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-04 | — | — | US | disclosed |
| US-7709487-B2 | anticancer agents; can be combined with other HDAC inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-04 | — | — | US | disclosed |
| US-7704998-B2 | anticancer agents; catalytic hydrogenation | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7704998-B2 | anticancer agents; catalytic hydrogenation | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | VAN EMELEN KRISTOF | 2008-05-08 | — | — | US | disclosed |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | VAN EMELEN KRISTOF | 2008-05-08 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 1/4885HDAC2 5/4885 |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 1/4885HDAC2 5/4885 |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 1/4885HDAC2 5/4885 |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.